top of page
oxmbio.com Syngeneic & Xenograft.jpg

ABOUT US

DOMESTIC QUALITY.  EXCEPTIONAL VALUE. 

 

Rincon runs high-quality in vivo cancer efficacy studies at our U.S. facilities, keeping your work close, protecting your IP, and making communication direct and easy. We bring the scientific experience you’d expect from a major CRO without all the layers and overhead.

SPEED TO INITIATION
 

Most studies initiate within two business days

DIRECT ACCESS

 

Work directly with the PhD running your study—not a rotating account manager. We stay responsive, flexible, and hands-on throughout the study.

Founded in 2013, Rincon Bio is a U.S.-based preclinical CRO focused on in vivo cancer efficacy studies, including xenograft and syngeneic models.

​

Our scientists have worked in pharma, academia, and major CROs and bring experience from thousands of in vivo studies for pharmaceutical, biotechnology, and academic organizations across North America, Europe, and Asia.

​

We intentionally operate with a small, experienced team. That means less bureaucracy, lower unnecessary overhead, and direct communication with the scientists running your study. It also gives us the flexibility to respond quickly when the science calls for a change.

​

All animal studies are run at our U.S.-based facilities, helping protect your IP and keeping communication straightforward from study design through final report.

MEET OUR SCIENTIFIC DIRECTOR

Bret Stephens, PhD
  • LinkedIn Social Icon

Bret brings more than 20 years of in vivo biology and cancer drug-discovery experience spanning pharmaceutical and academic research.

​

At Rincon, Bret remains directly involved in study design and execution—part of our approach of giving clients direct access to the scientists responsible for their work.

 

Dr. Stephens received his PhD degree in Molecular Biology from the University of Arizona.

 

Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.

Tell us about your planned study. We'll typically respond with a quotation within one business day.

Email: info@rinconbio.com
Tel:  760-713-6613

​

Utah: 

3900 N Traverse Mountain Blvd

Suite 100

Lehi, UT 84043

​

California: 

3156 Vista Way, Suite 220

Oceanside, CA 92056

 

CONTACT US
bottom of page